Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Fungal Infection Reports
Published in: Current Fungal Infection Reports 3/2021

01-09-2021 | Amphotericin B | Current Management of Fungal Infections (S Jacobs, Section Editor)

Investigational Agents for the Treatment of Resistant Yeasts and Molds

Authors: Garret T. Seiler, Luis Ostrosky-Zeichner

Published in: Current Fungal Infection Reports | Issue 3/2021

Login to get access

Abstract

Purpose of Review

This review summarizes the investigational antifungals in clinical development with the potential to address rising drug resistance patterns. The relevant pharmacodynamics, spectrum of activity, preclinical studies, and latest clinical trial data are described.

Recent Findings

Agricultural and medicinal antifungal use has been selected for inherently drug-resistant fungi and acquired resistance mechanisms. The rates of fungal infections and immunocompromised populations continue to grow as few new antifungals have hit the market. Several agents with the potential to address the emergence of multidrug-resistant (MDR) molds and yeasts are in clinical development.

Summary

Evolved formulations of echinocandins, polyenes, and triazoles offer less toxicity, convenient dosing, and greater potency, potentially expanding these classes’ indications. Ibrexafungerp, olorofim, oteseconazole, and fosmanogepix possess novel mechanisms of actions with potent activity against MDR fungi. Successful clinical development is neither easy nor guaranteed; thus, perpetual efforts to discover new antifungals are needed.
Literature
1.
Mourad A, Perfect J. Tolerability profile of the current antifungal armoury. Journal of Antimicrobial Chemotherapy. 2018;73:i26–32.CrossRef
2.
Gintjee T, Donnelley M, Thompson G. Aspiring antifungals: review of current antifungal pipeline developments. Journal of Fungi. 2020;6:28.CrossRef
3.
Vallabhaneni S, Mody R, Walker T, Chiller T. The global burden of fungal diseases. Infectious Disease Clinics of North America. 2016;30:1–11.CrossRef
4.
Lum L, Lee A, Vu M, Strasser S, Davis R. Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center. Transpl Inf Dis. 2020:e13361.
5.
6.
Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? The Lancet Infectious Diseases. 2009;9:789–95.CrossRef
7.
Casadevall A, Kontoyiannis DP, Robert V. On the emergence of Candida auris: climate change, azoles, swamps and birds. mBio. 2019;10:e01397–19.PubMedPubMedCentral
8.
Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. The Lancet Infectious Diseases. 2017;17:e383–92.CrossRef
9.
10.
11.
12.
Walker TA, Lockhart SR, Beekmann SE, Polgreen PM, Santibanez S, Mody RK, et al. Recognition of azole-resistant aspergillosis by physicians specializing in infectious diseases, United States. Emerging Infectious Diseases. 2018;24.
13.
14.
Ramirez-Garcia A, Pellon A, Rementeria A, Buldain I, Barreto-Bergter E, Rollin-Pinheiro R, et al. Scedosporium and Lomentospora: an updated overview of underrated opportunists. Medical Mycology. 2018;56(1):102–25.CrossRef
15.
16.
Schwarz P, Cornely OA, Dannaoui E. Antifungal combinations in Mucorales: a microbiological perspective. Mycoses. 2019;3:746–60.
17.
Tirado-Sánchez A, González GM, Bonifaz A. Endemic mycoses: epidemiology and diagnostic strategies. Expert Review of Anti-infective Therapy. 2020:1–13.
18.
CDC. Increase in reported coccidioidomycosis – United States, 1998-2011. MMWR. 2013;62(12):217–21.
19.
20.
Davis MR, Donnelley MA, Thompson GR. Ibrexafungerp: a novel oral glucan synthase inhibitor. Medical Mycology. 2020;58(8):579–92.CrossRef
21.
Wring SA, Randolph R, Park S, et al. Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis. Antimicrob Agents Chemother. 2017;61:e02068–16.CrossRef
22.
Wring S, Murphy G, Atiee G, Corr C, Hyman M, Willett M, et al. Lack of impact by SCY-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, a substrate for CYP450 2C8, supports the low risk for clinically relevant metabolic drug-drug interactions. The Journal of Clinical Pharmacology. 2018;58:1305–13.
23.
Carruthers C, Barat S, Angulo D, Thomas P, Lewis E, Sobel R. Ibrexafungerp, a novel oral antifungal, demonstrates no reproductive or developmental harm in preclinical models. Obstetrics & Gynecology. 2019;133:114S.CrossRef
24.
• Nunnally NS, Etienne KA, Angulo D, et al. In vitro activity of ibrexafungerp, a novel glucan synthase inhibitor against Candida glabrata isolates with FKS mutations. Antimicrob Agents Chemother. 2019;63:11. https://​doi.​org/​10.​1128/​AAC.​01692-19Ibrexafungerp has activity against echinocandin-resistant C. glabrata.CrossRef
25.
Barat S, Borroto-Esoda K, Angulo D. SCY-078 Demonstrates significant tissue penetration in rats and mice following oral or IV administration. Open Forum Infectious Diseases. 2017;4:S471–1.
26.
• Zhu YYC, Barat SA, Borroto-Esoda K, Angulo D, Chaturvedi S, Chaturvedi V. Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor). Int J Antimicrob Agents. 2020;55(4):105922. https://​doi.​org/​10.​1016/​j.​ijantimicagIbrexafungerp maintained against pan-resistant C. auris isolated from human patients in New York.CrossRefPubMed
27.
•• Spec A, Pullman J, Thompson GR III, Powderly WG, Tobin EH, Vazquez J, et al. MSG-10: a phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. J of Antimicrob Chemother. 2019;74(10):3056–62 Ibrexafungerp showed efficacy in phase II study for invasive candidiasis.
28.
29.
30.
31.
Krishnan BR, James KD, Polowy K, Bryant BJ, Vaidya A, Smith S, et al. CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility. J Antibiot. 2017;70:130–5.
32.
Tóth Z, Forgács L, Locke JB, Kardos G, Nagy F, Kovács R, et al. In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae. J Antimicrob Chemother. 2019;74:3505–10.
33.
Pfaller MA, Carvalhaes CG, Messer SA, Rhomberg PR, Castanheira M. Activity of a long-acting echinocandin rezafungin and comparator antifungal agents tested against contemporary invasive fungal isolates: (SENTRY Program, 2016 to 2018). Antimicrob Agents Chemother. 2020;64.
34.
Helleberg M, Jørgensen KM, Hare RK, Datcu R, Chowdhary A, Arendrup MC. Rezafungin In vitro activity against contemporary Nordic clinical Candida isolates and Candida auris determined by the EUCAST reference method. Antimicrob Agents Chemother. 2020;64.
35.
Hager CL, Larkin EL, Long LA, Ghannoum MA. Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J Antimicrob Chemother. 2018;73:2085–8.CrossRef
36.
•• Thompson GR, Vazquez J, Soriano A, Skoutelis A, Ostrosky-Zeichner L, Mena K, et al. Rezafungin clinical safety and efficacy in patients with candidemia and/or invasive candidiasis in the randomized, double-blind, multicenter, phase 2 STRIVE study. Open Forum Infect Dis 2018;5. Rezafungin is effective and safe for patients with candidemia or invasive candidiasis.
37.
Cushion MT, Collins MS. Susceptibility of pneumocystis to echinocandins in suspension and biofilm cultures. Antimicrob Agents Chemother. 2011;55:4513–8.CrossRef
38.
• Cushion M, Ashbaugh A. Rezafungin prophylactic efficacy in a mouse model of pneumocystis pneumonia. Biol Blood Marrow Tr. 2019;25 Preclinical data suggesting a potential role of rezafungin for pneumocystis pneumonia prophylaxis, offering a potential single agent prophylaxis regimen for certain stem cell transplant recipients or other immunocompromised patients.
39.
Wiederhold NP, Locke JB, Daruwala P, Bartizal K. Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species. J Antimicrob Chemother. 2018;73:3063–7.CrossRef
40.
• Driscoll E, Clancy CJ, Nguyen M-H. 738. Potent in vitro activity of rezafungin (RZF) against Aspergillus clinical isolates recovered from lung transplant patients who have received ≥3 months of triazole prophylaxis. Open Forum Infect Dis. 2019;6 Rezafungin may have potential as salvage therapy for invasive mold infections breaking through triazole prophylaxis.
41.
Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Wickes BL, Catano G, et al. Extended-interval dosing of rezafungin against azole-resistant Aspergillus fumigatus. Antimicrob Agents Chemother. 2019;63.
42.
43.
Warrilow AG, Parker JE, Price CL, et al. The tetrazole VT-1161 is a potent inhibitor of Trichophyton rubrum through its inhibition of T. rubrum CYP51. Antimicrob Agents Chemother. 2017;61:e00333–17.CrossRef
44.
Schell WA, Jones AM, Garvey EP, et al. Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds. Antimicrob Agents Chemother. 2017;61:e01817–6.PubMedPubMedCentral
45.
Gebremariam T, Wiederhold NP, Fothergill AW, Garvey EP, Hoekstra WJ, Schotzinger RJ, et al. VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection. Antimicrob Agents Chemother. 2015;59:7815–7.
46.
47.
• Elewski B, Brand S, Degenhardt T, Curelop S, Pollak R, Schotzinger R, et al. A phase II, randomized double-blinded, placebo controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail. Br J Dermatol. 2020. https://​doi.​org/​10.​1111/​bjd.​19224Phase II data showing efficacy for moderate to severe onychomycosis. Current antifungals for onychomycosis have low success rate, systemic toxicities and are primarily indicated for mild–moderate disease.
48.
• Brand SR, Degenhart TP, Person KL, et al. Oral VT-1161 is highly effective and safe in patients with recurrent vulvovaginal candidiasis - results of REVIVE, a multicenter phase 2b study. ASM Microbe. New Orleans: Viamet Pharmaceuticals. 2017; Phase II data supporting its use for recurrent vaginal candidiasis.
49.
Nishimoto AT, Wiederhold NP, Flowers SA, Zhang Q, Kelly SL, Morschhäuser J, et al. In vitro activities of the novel investigational tetrazoles vt-1161 and vt-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2019;63:1–11.
50.
Garvey EP, Hoekstra WJ, Schotzinger RJ, Sobel JD, Lilly EA, Fidel PL Jr. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother. 2015;59:5567–73.CrossRef
51.
Miyazaki M, Horii T, Hata K, Watanabe NA, Nakamoto K, Tanaka K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother. 2011;55:4652–8.
52.
Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies. J Antimicrob Chemother. 2019;74:1295–9.CrossRef
53.
Castanheira M, Duncanson FP, Diekema DJ, Guarro J, Jones RN, Pfaller MA. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. Antimicrob Agents Chemother. 2012;56:352–7.CrossRef
54.
Hager CL, Larkin EL, Long L, et al. In vitro and in vivo evaluation of the antifungal activity of APX001A/APX001 against Candida auris. Antimicrob Agents Chemother. 2018;62:e02319–7.CrossRef
55.
56.
57.
• Arendrup M, Chowdhary A, Jørgensen K, Meletiadis J. Manogepix (APX001A) in vitro activity against Candida auris. A head to head comparison of EUCAST and CLSI MICs. Antimicrob Agents Chemother. 2020. https://​doi.​org/​10.​1128/​AAC.​00656-20Fosmanogepix potently inhibits C. auris.
58.
• Wiederhold NP, Najvar LK, Shaw KJ, Jaramillo R, Patterson HP, Olivo M, et al. In vivo efficacy of delayed therapy with the novel inositol acyltransferase inhibitor fosmanogepix (APX001) in a murine model of Candida auris invasive candidiasis. Open Forum Infect Dis. 2019;6:S60–1. https://​doi.​org/​10.​1093/​ofid/​ofz359.​131In vivo efficacy against Candida auris.
59.
• Gebremariam T, Alkhazraji S, Alqarihi A, Wiederhold NP, Shaw KJ, Patterson TF, et al. Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to Rhizopus arrhizus. Antimicrob Agents Chemother. 2020;64(6):e00178–20. https://​doi.​org/​10.​1128/​AAC.​00178-20In vivo data supporting fosmanogepix in treating mucormycosis.
60.
• Alkhazraji S, Gebremariam T, Alqarihi A, et al. Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis. Antimicrob Agents Chemother. 2020;64(3):e01735–19. https://​doi.​org/​10.​1128/​AAC.​01735-19In vivo model demonstrating successful activity against often pan-resistant mold species.CrossRefPubMedPubMedCentral
61.
62.
63.
Oliver JD, Sibley GE, Beckmann N, et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci USA. 2016;113:12809–14.CrossRef
64.
65.
• Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies. J Antimicrob Chemother. 2019;74:1586–90 In vitro activity against cryptic (often MDR) Aspergillus species.CrossRef
66.
• Kirchhoff L, Dittmer S, Weisner A, Buer J, Rath P, Steinmann J. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus. Int J Antimicrob. 2020:0924–8579. https://​doi.​org/​10.​1016/​j.​ijantimicag.​2020.​106105Olorofim has in vitro activity against MDR molds without reliable treatments available.
67.
Wiederhold NP, Patterson HP, Birch M, Law D. Evaluation of the in vitro activity of olorofim against Fusarium species. In Proceedings of the 9th Trends in Medical Mycology, Nice, France, 11–19 October 2019.
68.
• Kirchhoff L, Dittmer S, Weisner A, Buer J, Rath P, and Steinmann J. Antibiofilm activity of antifungal drugs, including the novel drug olorofim, against Lomentospora prolificans. J Antimicrob Chemother 2020; https://​doi.​org/​10.​1093/​jac/​dkaa157. Olorofim has in vitro activity against Lomentospora spp. and penetrates biofilms. Currently antifungals have poor biofilm penetration. Biofilms significantly contribute to drug resistance.
69.
Hope W, McEntee L, Livermore J, Whalley S, Johnson A, Farrington N, et al. Pharmacodynamics of the orotomides against Aspergillus fumigatus: new opportunities for treatment of multidrug-resistant fungal disease. mBio. 2017;8:e01157–17.
70.
Negri C, Johnson A, McEntee L, Box H, Whalley S, Schwartz J, et al. Pharmacodynamics of the novel antifungal agent F901318 for acute sinopulmonary aspergillosis caused by Aspergillus flavus. J Infect Dis. 2017;217:1118–27.
71.
Seyedmousavi S, Chang YC, Law D, Birch M, Rex JH, Kwon-Chung KJ. Efficacy of olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease. Antimicrob Agents Chemother. 2019;63.
72.
Fothergill AW, Wiederhold NP, Sibley G, Kennedy A, Oliver J, Birch M, et al. Spectrum of activity of F901318, the first agent from the newly discovered orotomide class of antifungals. ICAAC/ICC. 2015.
73.
74.
75.
Delmas G, Park S, Chen ZW, Tan F, Kashiwazaki R, Zarif L, et al. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother. 2002;46:2704–7.
76.
77.
78.
• Skipper C, Atukunda M, Stadelman A, Engen N, Bangdiwala A, Hullsiek KH, et al. Safety and tolerability of a novel oral formulation of amphotericin B: phase I EnACT trial. Antimicrob Agents Chemother. 2020. https://​doi.​org/​10.​1128/​AAC.​00838-20Recent phase I data showing oral encochleated amphotericin B is easily tolerated with better safety compared to parenteral amphotericin B.
79.
Kibathi L, Kumar P, Lionakis M, Urban A, Ferre E, McManus M, et al. 1413. A phase IIa efficacy, safety, tolerability and pharmacokinetic (PK) study of encochleated amphotericin B in patients with mucocutaneous (esophageal, oropharyngeal, vulvovaginal) candidiasis who are refractory or intolerant to standard non-intravenous therapies. Open Forum Infect Dis. 2018;5(1):S435–5. https://​doi.​org/​10.​1093/​ofid/​ofy210.​1244.
80.
81.
Colley T, Alanio A, Kelly SL, Sehra G, Kizawa Y, Warrilow AGS, et al. In vitro and in vivo antifungal profile of a novel and long-acting inhaled azole, PC945, on aspergillus fumigatus infection. Antimicrob Agents Chemother. 2017;61(5):e02280–16. https://​doi.​org/​10.​1128/​aac.​02280-16.
82.
83.
84.
85.
Yamashita K, Miyazaki T, Fukuda Y, et al. The novel arylamidine T-2307 selectively disrupts yeast mitochondrial function by inhibiting respiratory chain complexes. Antimicrob Agents Chemother. 2019;63:e00374–19.PubMedPubMedCentral
86.
Mitsuyama J, Nomura N, Hashimoto K, Yamada E, Nishikawa H, Kaeriyama M, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother. 2008;52:1318–24.
87.
Nishikawa H, Fukuda Y, Mitsuyama J, Tashiro M, Tanaka A, Takazono T, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen. J Antimicrob Chemother. 2017;72:1709–13.
88.
Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, et al. The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata. J Antimicrob Chemother. 2016;71:692–5.
89.
90.
Abe M, Nakamura S, Kinjo Y. Efficacy of T-2307, a novel arylamidine, against ocular complications of disseminated candidiasis in mice. J Antimicrob Chemother. 2019;74:1327–32.CrossRef
91.
92.
Lockhart SR, Fothergill AW, Iqbal N, Bolden CB, Grossman NT, Garvey EP, et al. The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against Cryptococcus neoformans and Cryptococcus gattii. Antimicrob Agents Chemother. 2016;60:2528–31.
93.
94.
Wiederhold NP, Najvar LK, Garvey EP, Brand SR, Xu X, Ottinger EA, et al. The fungal Cyp51 inhibitor VT-1129 is efficacious in an experimental model of cryptococcal meningitis. Antimicrob Agents Chemother. 2018;62.
95.
96.
Wiederhold NP, Patterson HP, Tran BH, Yates CM, Schotzinger RJ, Garvey EP. Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus. J Antimicrob Chemother. 2018;73(2):404–8. https://​doi.​org/​10.​1093/​jac/​dkx410.CrossRefPubMed
97.
Nishimoto A, Whaley S, Wiederhold N, Zhang Q, Yates C, Hoekstra W, et al. Impact of the major Candida glabrata triazole resistance determinants on the activity of the novel investigational tetrazoles VT-1598 and VT-1161. Antimicrob Agents Chemother. 2019;63.
98.
Wiederhold NP, Lockhart SR, Najvar LK, et al. The fungal Cyp51-specific inhibitor VT-1598 demonstrates in vitro and in vivo activity against Candida auris. Antimicrob Agents Chemother. 2019;63:e02233–18.PubMedPubMedCentral
99.
100.
Wiederhold NP, Shubitz LF, Najvar LK, et al. The novel fungal Cyp51 inhibitor VT-1598 is efficacious in experimental models of central nervous system coccidioidomycosis caused by Coccidioides posadasii and Coccidioides immitis. Antimicrob Agents Chemother. 2018;62:e02258–17.PubMedPubMedCentral
101.
Hector RF, Zimmer BL, Pappagianis D. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis. Antimicrob Agents Chemother. 1990;34:587–93.CrossRef
102.
Shubitz LF, Roy ME, Nix DE, Galgiani JN. Efficacy of nikkomycin Z for respiratory coccidioidomycosis in naturally infected dogs. Med Mycol. 2013;51:747–54.CrossRef
103.
Cheung Y-Y, Hui M. Effects of echinocandins in combination with nikkomycin Z against invasive Candida albicans bloodstream isolates and the fks mutants. Antimicrob Agents Chemother. 2017;61:e00619–7.CrossRef
104.
Nix DE, Swezey RR, Hector R, Galgiani JN. Pharmacokinetics of nikkomycin Z after single rising oral doses. Antimicrob Agents Chemother. 2009;53:2517–21.CrossRef
105.
Pfaller MA, Messer SA, Georgopapadakou N, Martell LA, Besterman JM, Diekema DJ. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol. 2009;47:3797–804.CrossRef
106.
Metadata
Title
Investigational Agents for the Treatment of Resistant Yeasts and Molds
Authors
Garret T. Seiler
Luis Ostrosky-Zeichner
Publication date
01-09-2021
Publisher
Springer US
Published in
Current Fungal Infection Reports / Issue 3/2021
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-021-00419-5

Other articles of this Issue 3/2021

Current Fungal Infection Reports 3/2021 Go to the issue

Clinical Mycology Lab Issues (S Challa, Section Editor)

Cytopathology of Fungal Infections

Fungal Infections in Transplantation (S Shoham, Section Editor)

Scedosporium and Lomentospora infections in lung transplant recipients

Clinical Mycology Lab Issues (S Cordoba, Section Editor)

Emergence of Triazole Resistance in Aspergillus spp. in Latin America

Advances in Diagnosis of Invasive Fungal Infections (O Morrissey, Section Editor)

Candida auris: Diagnostic Challenges and Emerging Opportunities for the Clinical Microbiology Laboratory

Clinical Pathology (S Challa, Section Editor)

Molecular Diagnosis of Yeast Infections

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits